Marieke van Son

18 CHAPTER 1 REFERENCES 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394-424. 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: a cancer journal for clinicians. 2020;70(1):7-30. 3. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. The Cochrane database of systematic reviews. 2013(1):CD004720. 4. Sheng IY, Wei W, Chen YW, Gilligan TD, Barata PC, Ornstein MC, et al. Implica- tions of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage Migration. Clinical genitourinary cancer. 2020. 5. Hugosson J, Roobol MJ, Mansson M, Tammela TLJ, Zappa M, Nelen V, et al. A 16-yr Follow-up of the European Ran- domized study of Screening for Prostate Cancer. Eur Urol. 2019;76(1):43-51. 6. Force USPST, Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. Jama. 2018;319(18):1901-13. 7. Horwich A, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V, et al. Pros- tate cancer: ESMO Consensus Con- ference Guidelines 2012. Annals of oncology : official journal of the Eu- ropean Society for Medical Oncology. 2013;24(5):1141-62. 8. American Cancer Society. Cancer Facts & Figures 2020. Atlanta: American Cancer Society; 2020. 9. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Prostate Cancer. [Available from: https://seer. cancer.gov/statfacts/html/prost.html. 10. Brierley JD, Gospodarowicz MK, Wit- tekind C. TNM classification of malig- nant tumors. UICC International Union Against Cancer. 8th edn. 2017. 11. Drost FH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting pros- tate cancer. The Cochrane database of systematic reviews. 2019;4:CD012663. 12. Schoots IG, Roobol MJ. Multivariate risk prediction tools including MRI for indi- vidualized biopsy decision in prostate cancer diagnosis: current status and future directions. World journal of urol- ogy. 2020;38(3):517-29. 13. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaara- la MH, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018;378(19):1767-77. 14. Rouviere O, Puech P, Renard-Penna R, Claudon M, Roy C, Mege-Lechevallier F, et al. Use of prostate systematic and targeted biopsy on the basis of multi- parametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. The Lancet On- cology. 2019;20(1):100-9. 15. van der Leest M, Cornel E, Israel B, Hen- driks R, Padhani AR, HoogenboomM, et al. Head-to-head Comparison of Transrec- tal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Reso- nance Imagingwith Subsequent Magnetic Resonance-guided Biopsy in Biopsy-na- ive Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. Eur Urol. 2019;75(4):570-8. 16. Connor MJ, Eldred-Evans D, van Son M, Hosking-Jervis F, Bertoncelli Tanaka M, Reddy D, et al. A Multicentre Study of the Clinical Utility of Non-targeted Systematic Transperineal Prostate Bi- opsies in Patients Undergoing Pre-bi- opsy mpMRI. The Journal of urology. 2020:101097JU0000000000001184.